The ascendancy of Viagra and its influence on the pharmaceutical landscape presents a complex question for investors. While the first sales figures were astounding, the intellectual property has lapsed, leading to a deluge of generic alternatives that are eroding profit. Moreover, the market is facing difficulties related to demographic trends and